首页> 美国卫生研究院文献>AAPS PharmSciTech >Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration
【2h】

Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration

机译:固体脂质微粒作为肺部给药载体的制备及体内毒性研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The purpose of this research was to investigate the effects of processing conditions on the characteristics of solid lipid microparticles (SLM) with a potential application as carriers for pulmonary administration. Compritol (5.0% wt/wt) SLM dispersions were prepared by rotor-stator homogenization, at different surfactant concentrations and emulsification times. The SLM were characterized, in terms of morphology and size, after lyophilization and sterilization by autoclaving process. In vivo assessment was carried out in rats by intratracheal instillation of either placebo or SLM dispersion, and by bronchoalveolar lavage for cytological analysis. Mean particle size of 4 to 5 μm was achieved using 0.3% and 0.4% (wt/wt) of emulsifier (Poloxamer 188) and emulsification times of 2 and 5 minutes. The particles showed spherical shape and smooth surface. The morphology of microparticles, the size, and the size distribution were not substantially modified after lyophilization and sterilization. Total cell counts showed no significant differences between placebo and SLM 0.5% or 2.5% groups. Regarding cytology, percentage of polymorphonuclear neutrophils and macrophages did not significantly differ between groups. These results suggest that a single intratracheal administration of the SLMs does not induce a significant inflammatory airway response in rats and that the SLMs might be a potential carrier for encapsulated drug via the pulmonary route.
机译:这项研究的目的是研究加工条件对固体脂质微粒(SLM)特性的影响,并可能作为肺部给药的载体。通过转子-定子均质,在不同的表面活性剂浓度和乳化时间下制备Compritol(5.0%wt / wt)SLM分散体。冻干和高压灭菌后,根据形态和大小对SLM进行表征。通过气管内滴注安慰剂或SLM分散液,并通过支气管肺泡灌洗进行细胞学分析,在大鼠中进行体内评估。使用0.3%和0.4%(wt / wt)的乳化剂(Poloxamer 188)以及2分钟和5分钟的乳化时间可实现4至5μm的平均粒径。颗粒显示球形和光滑表面。冻干和灭菌后,微粒的形态,尺寸和尺寸分布没有实质改变。总细胞计数显示安慰剂组和SLM 0.5%或2.5%组之间无显着差异。关于细胞学,两组之间多形核中性粒细胞和巨噬细胞的百分比没有显着差异。这些结果表明,单次气管内施用SLM不会在大鼠中引起明显的炎症性气道反应,并且SLM可能是通过肺部途径封装药物的潜在载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号